Abstract Library

#4446 Uncommon ophthalmic presentation of a small bowel neuroendocrine tumour: Case report

Introduction: Neuroendocrine tumours (NETs), including carcinoid tumours, are slow-growing neoplasms commonly originating in the gastrointestinal tract or bronchus, but they can also arise in other sites. Due to their indolent nature, the majority of NETs are diagnosed at an advanced stage, typically to the lymph nodes, liver, or bones.

Conference:

Presenting Author:

Authors: Hamidatou K, Behourah Z, Ahed Messaoud M, Megaiz A, Lechar M,

Keywords: Neuroendocrine tumour, Carcinoid tumour, Orbital metastasis, somatostatin analogue injection,

#3289 Short-interval, low-dose (SILD) Lu-177 DOTAiTATE therapy to overcome resistance to immunotherapy with PD-1 checkpoint inhibitors: Proof of concept to induce remission in patients with metastatic Merkel cell carcinoma and melanoma

Introduction: Immunotherapy with PD-1 immune checkpoint inhibitors (ICI) in Merkel cell carcinoma (MCC) or melanoma have proven efficacy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Aicher A, Sindrilaru A, Beer A, Prasad V,

Keywords: PRRT, SILD, ICI, Merkel cell carcinoma, melanoma, tumor microenvironment remodelling,

#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,

#2297 Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?

Introduction: Merkel Cell Carcinoma (MCC) is a rare Neuroendocrine skin tumour. MCC behavior is more aggressive than the more common Melanoma, with treatments often restricted to surgery or radiotherapy, although immunotherapy holds promise overseas. In 2008, a USA study identified an oncogenic polyomavirus (MCPyV) present in eight of ten tested MCC tumours. Studies from across Europe and the USA confirmed MCPyV presence in ~80% of all MCCs. However, a cohort from Australia found a rate of just 24%, suggesting an alternative mechanism; ultra violet (UV) exposure was suspected and later confirmed using genomic mutational signature analysis. Are these are two separate diseases, requiring different clinical management strategies for best patient outcomes?

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Robb T

Authors: Robb T, Woodhouse B, Parker K, Miller R, Hayward G,

Keywords: merkel, ddPCR, diagnostics, genomics,

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,